0 CHECKOUT

Pertussis - Pipeline Review, H2 2015

  • ID: 3500425
  • October 2015
  • 98 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Biological E. Limited
  • GlaxoSmithKline Plc
  • Immunovaccine, Inc.
  • NanoBio Corporation
  • Sanofi
  • Sinovac Biotech Ltd.
  • MORE

Pertussis - Pipeline Review, H2 2015

Summary

The report ‘Pertussis - Pipeline Review, H2 2015’, provides an overview of the Pertussis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pertussis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pertussis and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Biological E. Limited
  • GlaxoSmithKline Plc
  • Immunovaccine, Inc.
  • NanoBio Corporation
  • Sanofi
  • Sinovac Biotech Ltd.
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Pertussis Overview

Therapeutics Development

Pipeline Products for Pertussis - Overview

Pipeline Products for Pertussis - Comparative Analysis

Pertussis - Therapeutics under Development by Companies

Pertussis - Therapeutics under Investigation by Universities/Institutes

Pertussis - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Pertussis - Products under Development by Companies

Pertussis - Products under Investigation by Universities/Institutes

Pertussis - Companies Involved in Therapeutics Development

Beijing Minhai Biotechnology Co., Ltd

Beijing Tiantan Biological Products Co., Ltd.

Bharat Biotech International Limited

Biological E. Limited

Boryung Pharmaceutical Co., Ltd.

Daiichi Sankyo Company, Limited

DBV Technologies S.A.

GlaxoSmithKline Plc

Green Cross Corporation

Immunovaccine, Inc.

Indian Immunologicals Limited

LG Life Sciences Limited

NanoBio Corporation

Panacea Biotec Limited

Sanofi

Sanofi Pasteur SA

Serum Institute of India Limited

Sinovac Biotech Ltd.

Synthetic Biologics, Inc.

Zydus Cadila Healthcare Limited

Pertussis - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(diphtheria + tetanus + pertussis (acellular) + poliovirus) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

(diphtheria + tetanus + pertussis (whole-cell) + haemophilus influenzae [serotype B]) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

(diphtheria + tetanus + pertussis (whole-cell)) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

(diphtheria + tetanus + pertussis) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

diphtheria + pertussis (acellular) + tetanus vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

diphtheria + pertussis (acellular) + tetanus vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

diphtheria + pertussis + tetanus + hepatitis B + haemophilus influenza [serotype B] vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

diphtheria + tetanus + pertussis (acellular) + haemophilus influenza [serotype B] + polio [sabin] vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

diphtheria + tetanus + pertussis (acellular) + haemophilus influenza [serotype B] vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

diphtheria + tetanus + pertussis (acellular) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

diphtheria + tetanus + pertussis (acellular) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

diphtheria + tetanus + pertussis (acellular) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

diphtheria + tetanus + pertussis (whole cell) + haemophilus influenzae [serotype B] + polio (pentavalent) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B] + polio (hexavalent) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] (pentavalent) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

diphtheria + tetanus + pertussis (whole-cell) + poliomyelitis + haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] (7-valent) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

diphtheria + tetanus+ pertussis (whole cell) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + haemophilus influenzae [type B] (pentavalent) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + poliomyelitis + haemophilus influenzae [type B] (hexavalent) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

GC-3111A - Drug Profile

Product Description

Mechanism of Action

R&D Progress

pertussis (acellular) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

pertussis (acellular) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

pertussis (acellular) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

pertussis (acellular) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

pertussis (whole-cell) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

pertussis + hepatitis B vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

pertussis vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

pertussis vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

pertussis vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PR-5I - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Recombinant BCG - Pertussis Vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SYN-005 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

tetanus + diphtheria + pertussis (acellular) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

VN-0103 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Pertussis - Recent Pipeline Updates

Pertussis - Dormant Projects

Pertussis - Discontinued Products

Pertussis - Product Development Milestones

Featured News & Press Releases

Apr 27, 2015: Posters at ECCMID 2015 Highlight Preclinical Data from Synthetic Biologics' Novel SYN-005 Monoclonal Antibody Combination for the Treatment and Prophylaxis of Whooping Cough (Pertussis)

Nov 14, 2014: Biological E To Supply Pentavalent Vaccine For Telangana State Immunization Program

Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur’s Investigational Pediatric Hexavalent Vaccine

Oct 16, 2014: BioNet Provides Update on Recombinant Acellular Pertussis Vaccine at BioJapan 2014

Sep 12, 2014: Synthetic Biologics Receives Orphan Drug Designation for SYN-005 Treatment for Whooping Cough (Pertussis)

Sep 08, 2014: Synthetic Biologics Highlights SYN-005 Data Presented at the 54th ICAAC from Novel Whooping Cough (Pertussis) Program

Aug 19, 2014: Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC

Apr 23, 2014: Synthetic Biologics' Reports Preclinical Data to Support Clinical Development of Novel Pertussis Therapeutic

Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel® Tdap Vaccine to Include Persons 10 Years of Age

Dec 20, 2012: Synthetic Biologics And Intrexon Initiate Development Of Monoclonal Antibodies For Whooping Cough

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Pertussis, H2 2015

Number of Products under Development for Pertussis - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Development by Companies, H2 2015 (Contd..1)

Products under Investigation by Universities/Institutes, H2 2015

Pertussis - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2015

Pertussis - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H2 2015

Pertussis - Pipeline by Bharat Biotech International Limited, H2 2015

Pertussis - Pipeline by Biological E. Limited, H2 2015

Pertussis - Pipeline by Boryung Pharmaceutical Co., Ltd., H2 2015

Pertussis - Pipeline by Daiichi Sankyo Company, Limited, H2 2015

Pertussis - Pipeline by DBV Technologies S.A., H2 2015

Pertussis - Pipeline by GlaxoSmithKline Plc, H2 2015

Pertussis - Pipeline by Green Cross Corporation, H2 2015

Pertussis - Pipeline by Immunovaccine, Inc., H2 2015

Pertussis - Pipeline by Indian Immunologicals Limited, H2 2015

Pertussis - Pipeline by LG Life Sciences Limited, H2 2015

Pertussis - Pipeline by NanoBio Corporation, H2 2015

Pertussis - Pipeline by Panacea Biotec Limited, H2 2015

Pertussis - Pipeline by Sanofi, H2 2015

Pertussis - Pipeline by Sanofi Pasteur SA, H2 2015

Pertussis - Pipeline by Serum Institute of India Limited, H2 2015

Pertussis - Pipeline by Sinovac Biotech Ltd., H2 2015

Pertussis - Pipeline by Synthetic Biologics, Inc., H2 2015

Pertussis - Pipeline by Zydus Cadila Healthcare Limited, H2 2015

Assessment by Monotherapy Products, H2 2015

Assessment by Combination Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Pertussis Therapeutics - Recent Pipeline Updates, H2 2015

Pertussis - Dormant Projects, H2 2015

Pertussis - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Pertussis, H2 2015

Number of Products under Development for Pertussis - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Assessment by Combination Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

Beijing Minhai Biotechnology Co., Ltd
Beijing Tiantan Biological Products Co., Ltd.
Bharat Biotech International Limited
Biological E. Limited
Boryung Pharmaceutical Co., Ltd.
Daiichi Sankyo Company, Limited
DBV Technologies S.A.
GlaxoSmithKline Plc
Green Cross Corporation
Immunovaccine, Inc.
Indian Immunologicals Limited
LG Life Sciences Limited
NanoBio Corporation
Panacea Biotec Limited
Sanofi
Sanofi Pasteur SA
Serum Institute of India Limited
Sinovac Biotech Ltd.
Synthetic Biologics, Inc.
Zydus Cadila Healthcare Limited

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Sanofi S.A.
  • GlaxoSmithKline PLC
  • Astrazeneca PLC
  • Invacare Corporation
  • Boehringer Ingelheim GmbH
  • Takeda Pharmaceutical Company Limited